profit from every $100 of sales.
$0$100
Zevra Therapeutics
$11.85-0.59% today
+25.7% in 1 year
1-year low $8.101-year high $14.75
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $8.47 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Zevra Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $10.2 million in 2022 to $106 million in 2025, with $83.2 million of profit last year.
SalesProfit
Zevra Therapeutics vs. similar companies
Zevra Therapeutics grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Zevra Therapeutics | 8.5× · Cheap | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Zevra Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 10 | 27 | 24 | 106 | |
| 10 | 25 | 16 | 90 | |
| -25 | -50 | -87 | -4 | |
| -26 | -44 | -76 | 99 | |
| -27 | -46 | -106 | 83 | |
| -1.20 | -1.30 | -2.28 | 1.35 | |
| 97.8% | 92.1% | 68.6% | 84.5% | |
| -245.1% | -180.6% | -368.5% | -4.0% | |
| -263.5% | -167.7% | -446.9% | 78.2% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 115 | 172 | 178 | 285 |
| Cash | 65 | 43 | 34 | 62 |
| Total debt | 14 | 44 | 60 | 63 |
| Total liabilities | 40 | 110 | 138 | 130 |
| 75 | 62 | 40 | 155 | |
| 34 | 35 | 46 | 57 | |
| -23.4% | -33.3% | -65.4% | 34.3% | |
| -35.6% | -74.4% | -266.0% | 53.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -19 | -34 | -70 | -2 | |
| 0 | 0 | – | 1 | |
| -19 | -34 | -70 | -2 | |
| Dividends paid | – | – | – | – |
| 5 | 3 | 0 | – | |
| 4 | 6 | 15 | 13 |
Valuation
- 8.5×
- 24.3×
- –
- 3.3×
- 6.6×
- –
- 7.2×
- -0.3%
- 11.8%
- 0.0%
Profitability
- 84.5%
- -4.0%
- 78.2%
- 86.9%
- -19.6%
- -29.2%
- 81.3%
- 44.6%
- -21.1%
- 11.3%
Growth
- +118.8%
- –
- +96.5%
- –
- +16.8%
Financial health
- 0.0×
- 0.01
- 0.4%
- -11.3×
- 4.89
- 4.84
- 0.44
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 20%of 958
Bottom 17%of 888
Top 7%of 600
Top 5%of 889
Bottom 36%of 987
What analysts expect
- Average price target
- $24.25
- Range
- $23.00 – $26.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | 0.18 | 0.06 | +200.0% |
| Mar 9, 2026 | 1.16 | 0.05 | +2,201.6% |
| Nov 5, 2025 | -0.01 | -0.02 | +50.0% |
| Aug 12, 2025 | 1.21 | 2.19 | −44.7% |
| May 13, 2025 | -0.06 | -0.21 | +71.4% |
| Mar 11, 2025 | -0.67 | -0.39 | −71.8% |
| Nov 12, 2024 | -0.69 | -0.44 | −56.8% |
| Aug 13, 2024 | -0.48 | -0.47 | −2.1% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
40No pass
Benjamin Graham
64Pass
Philip Fisher
56No pass
Peter Lynch
100Pass
Joel Greenblatt
56No pass
Charlie Munger
47No pass
Terry Smith
38No pass
Questions about Zevra Therapeutics
Is Zevra Therapeutics a good stock to buy?
A strong, very profitable business, and the price looks low. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Zevra Therapeutics AI analysis
What does Zevra Therapeutics do?
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. It is in Biotechnology.
Does Zevra Therapeutics pay a dividend?
No. Zevra Therapeutics does not pay a dividend at the moment.
Is Zevra Therapeutics stock halal?
Yes. Zevra Therapeutics passes our halal screen: its business is permitted and its debt is 9% of its market value, under the 30% limit. How we check
How has Zevra Therapeutics stock done over the past year?
Up 25.7% over the past twelve months, to $11.85. It traded between $8.10 and $14.75 and is 19.7% below its high.
Who are Zevra Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Zevra Therapeutics's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.